It had been demonstrated that Wnt/β-catenin could be activated in kidney disease and the level of urinary MMP-7 might be used as a noninvasive surrogate biomarker (Liu Z et al., 2020) and a therapeutic target for renal fibrosis (Wozniak et al., 2021). This evidence concerns the gene MMP7 and renal fibrosis.